Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Eric Venker, President and Immunovant (NASDAQ:IMVT) CEO at Roivant Sciences Ltd (NASDAQ:ROIV), sold 100,000 common shares of the company on July 21, 2025, for $11.52 each, totaling $1.15 million. The transaction comes as the $7.8 billion market cap company trades near its 52-week high of $13.05, with InvestingPro analysis indicating the stock is currently overvalued.
According to a Form 4 filing with the Securities and Exchange Commission, the executive also exercised options to acquire 100,000 common shares at a price of $3.85, for a total value of $385,000. The company maintains a strong balance sheet, with more cash than debt and a healthy current ratio of 33.47x, according to InvestingPro data.
Following the sale, Venker directly owns 1,462,223 shares of Roivant Sciences. For deeper insights into insider trading patterns and 10+ additional ProTips about ROIV, including management’s share buyback activity, visit InvestingPro.
In other recent news, Roivant Sciences has made significant developments that are catching the attention of investors. The company announced a new common share repurchase program, authorizing up to $500 million in buybacks. This follows a previous $1.5 billion program, which has now been fully utilized. On the analyst front, Goldman Sachs resumed coverage of Roivant Sciences with a Buy rating and a price target of $19.00. Cantor Fitzgerald and H.C. Wainwright both reiterated their positive outlooks, maintaining their overweight and buy ratings, respectively. Cantor Fitzgerald anticipates the results of the Phase 3 trial for the drug brepocitinib in dermatomyositis by late 2025, with a potential market launch in early 2027. Meanwhile, H.C. Wainwright highlighted the upcoming trial results as a key catalyst for the company. Guggenheim also maintains a Buy rating, focusing on the ongoing Phase III VALOR study for brepocitinib. These developments suggest a strong focus on advancing clinical trials and strategic financial moves.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.